Medscape6d
FDA Approves Inavolisib for HR+, HER2−, Advanced Breast Cancer With PIK3CA Mutation
The FDA also approved the FoundationOne Liquid CDx assay to identify patients who qualify for the newly approved treatment.
The American Journal of Managed Care5d
FDA Approves Inavolisib in Locally Advanced, Metastatic Breast Cancer
Patients with endocrine-resistant, HER2-negative, locally advanced or metastatic breast cancer can use the treatment after ...
FDA approves Itovebi for locally advanced, metastatic breast cancer
The U.S. Food and Drug Administration has approved Itovebi (inavolisib), in combination with palbociclib (Ibrance) and ...
Targeted Oncology6d
FDA Approves Inavolisib Plus Standard Therapy in PIK3CA-Mutant Breast Cancer
The approval of inavolisib is supported by findings from the phase 3 INAVO120 study evaluating the agent plus palbociclib and ...
Medpage Today on MSN6d
PI3K Inhibitor Wins FDA Approval for Advanced Breast Cancer
The FDA approved the PI3K-pathway inhibitor inavolisib (Itovebi) for use in combination with palbociclib (Ibrance) and ...
InnovationRx: This Startup’s Emotion-Sensing Glasses Could Be Used To Improve Mental Health
InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here.
BioSpace5d
Roche Wins First-Line Breast Cancer Nod for Oral PI3K Blocker, Projects $2.3B in Peak Sales
With the regulatory approval for advanced breast cancer, Roche’s inavolisib is a potential challenger to Novartis’ PI3K ...
FiercePharma6d
Roche burnishes breast cancer portfolio with FDA approval for Itovebi, a threat to Novartis and AZ
As Roche comes under competitive pressure on its breast cancer business, the Swiss company hopes a new drug will add a ...
MedPage Today7d
PI3K Inhibitor Wins FDA Approval for Advanced Breast Cancer
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved the PI3K-pathway inhibitor inavolisib (Itovebi) for use in combination with palbociclib (Ibrance ...
FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Approval is based on Phase III INAVO120 results, showing the Itovebiâ„¢ (inavolisib)-based regimen more than doubled ...